NextCure, Inc.
NXTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001661059
Insider trades, last 90 days
2 buys · 1 sell
- Bought $1.71M
- Sold $184.8K
- Open-market purchases (P) and sales (S), counted by Form 4 filing.
13F holders, Q2 2026
30
- +4 vs. Q1 2026
- Total value $2.78M
Superinvestors holding NXTC
0
- None of the superinvestors held NXTC at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by NXTC insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 202611:35 AM ET | Aug 10, 2026 | Ren Jinsheng and 5 othersOther: Former 10% Owner | SSaleCommon Stock | −30K | $6.16 | −$184.8K | 308.64K | −8.9% | SEC |
| Aug 3, 20265:53 PM ET | Jul 30 – Jul 31, 2026 | Schneeberger Daniel and 1 other10% Owner | PPurchaseCommon Stock | +329.15K | $4.9342 | +$1.62M | 722.42K | +83.7% | SEC |
| Jul 29, 20266:18 PM ET | Jul 27 – Jul 29, 2026 | Schneeberger Daniel and 1 other10% Owner | PPurchaseCommon Stock | +17.61K | $4.9814 | +$87.71K | 393.27K | +4.7% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in NXTC at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 288,303 | $461.28K | 0.08% | +50,000+21.0% | Added |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 277,202 | $443.52K | 0.00% | +277,202 | New |
| Sofinnova Investments, Inc. | 222,654 | $356.25K | 0.02% | 00.0% | Unchanged |
| RENAISSANCE TECHNOLOGIES LLC | 171,202 | $273.92K | 0.00% | +110,668+182.8% | Added |
| VANGUARD CAPITAL MANAGEMENT LLC | 156,842 | $250.95K | 0.00% | −3,631−2.3% | Reduced |